Novo Nordisk, the Danish pharmaceutical giant renowned for its diabetes and obesity treatments, experienced its largest stock decline ever, with shares plummeting 23.11% in a single day. This dramatic fall followed a downward revision of growth forecasts for 2025: expected sales growth was revised from 13–21% to 8–14%.
Coincidentally, the company also announced a new CEO, Maziar Mike Doustdar, who will assume leadership on 7 August. However, the leadership change and the stock decline are not directly related, according to company sources and analysts.
The market reaction wiped approximately DKK 465 billion (approx. €62.3 billion) from Novo Nordisk’s market value, raising concerns about its growth strategy and competition in the global obesity drug market.
Maziar Mike Doustdar: a veteran insider with a new tone
Doustdar, a 54-year-old Austrian citizen born in Iran and raised in the United States, has been with Novo Nordisk for over three decades. He began his career at the company in 1992 as a clerk in Vienna and rose through the ranks, holding roles in finance, IT, logistics, operations, and marketing. Most recently, he served as Executive Vice President for International Operations.
Despite internal continuity, analysts note a shift in leadership style. Doustdar is described as adopting a more assertive and performance-driven approach than his predecessor, Lars Fruergaard Jørgensen, who had led the company since 2017. His first statements have set a combative tone, pledging an “unwavering determination” to aim higher than ever before.
USA market and competition from Eli Lilly
One of Doustdar’s main challenges will be to regain momentum in the USA market, where rival Eli Lilly has made significant gains with its obesity drug offerings. While Novo Nordisk traditionally focused on patients with clinical obesity, Eli Lilly has successfully targeted a broader consumer base interested in weight loss, capturing a notable share of the U.S. market.
Adding to the pressure, generic manufacturers have launched copycat products, prompting Novo Nordisk to take legal action and warn against potentially unsafe alternatives. The company also faces calls to shorten development cycles and deliver new treatments faster to stay competitive.
Organisational changes and efficiency drive
Internally, Doustdar is expected to lead a streamlining of Novo Nordisk’s operations. With approximately 77,000 employees, the company has grown rapidly in recent years, especially to meet production demands. By contrast, Eli Lilly operates with just 45,000 staff and a higher turnover, suggesting potential overcapacity.
Though no official layoffs have been announced, Doustdar has already flagged the need for cost savings and prioritisation, particularly in “less critical areas”. A strategic realignment focusing on fewer, more impactful objectives is anticipated in the months ahead.
Uncertainty ahead despite leadership shift
While the appointment of a seasoned insider like Doustdar brings a sense of continuity, it remains uncertain whether this change at the top can restore investor confidence. The record-breaking market drop underscores the urgency of delivering not just bold rhetoric, but tangible results in the face of intensifying global competition and shifting market expectations.
